Hamps Bio Limited IPO

We are engaged in the ethical marketing and distribution of pharmaceutical formulation products (Pharma) across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products (FDFP) such as fruits, vegetables, herbs and flowers. We are recognized in the pharmaceutical industry under our own brand name Hamps and in freeze-dried and frozen food segment through our own brand FzyEzy. We sell our products through more than 50 distributor's network as on October 31, 2024 and E-commerce platform, including Amazon.com, Amazon.ca, Amazon.eu, Flipkart, Jio Mart, Etc. We sell our pharma products primarily in 8 States and Union territories and our FDFP products primarily in 6 countries and 22 States and Union territories. As on the date of this Prospectus, we had a range of more than 180 different products sold across both the segments.

Open Demat Account

50years

Hamps Bio Limited IPO Details

Details

Total Shares OfferedOffer to PublicRetail Max (Shares)Pre Issue Promoters HoldingExchangeIssue size
₹ 12.2 LTBA₹ 5.8 L₹ 31.36 LBSETBA
IPO Open DateClose DateLot SizeMin InvestmentIssue TypeListing Date
13 Dec, 2417 Dec, 242000 TBA Fixed Price - SME20 Dec, 24

Hamps Bio Limited IPO Dates

  • 13 Dec 2024

    Opening date

  • 17 Dec 2024

    Closing date

  • 18 Dec 2024

    Basis of
    Allotment

  • 19 Dec 2024

    Initiation of
    Refunds

  • 19 Dec 2024

    Credit of
    Shares

  • 20 Dec 2024

    Listing date

Details

SectorType
SectorTrading
Sub SectorNA
Issue TypeFixed Price - SME

Subscription Status

*Values are in Lakhs

Investor TypeSubscription TimesShares Offered*Shares Bid*
QIB0x00
NII0x5780000
Retail0x5800000
Employee0x00
Total0x12200000

Subscription Status

Investor Type

QIB

NII

Retail

Employee

Total

*Values are in Lakhs

Hamps Bio Limited Financial Status

Income Statement

Balance Sheet

Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations1.050.700.43
EBITDA1.451.040.76
PAT0.500.360.12
Total Assets2.491.271.37
Share Capital1.961.501.50
Total Borrowings1.101.391.71
Operating Activities (Net Cash)0.900.700.45
Investing Activities (Net Cash)0.000.000.04
Financing Activities (Net Cash)1.101.391.71
Net Cashflow0.060.050.05

Particulars (in Rs. Crores)

Revenue from operations

EBITDA

PAT

Total Assets

Share Capital

Total Borrowings

Operating Activities (Net Cash)

Investing Activities (Net Cash)

Financing Activities (Net Cash)

Net Cashflow

About Hamps Bio Limited

Our Company was originally incorporated under the name Hamps Bio Private Limited under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli on January 02, 2007. Subsequently, the status of the Company was changed to public limited and the name of our Company was changed to Hamps Bio Limited vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on June 08, 2023. The fresh certificate of incorporation consequent to conversion was issued on July 12, 2023 by the Registrar of Companies, Ahmedabad, Gujarat. The Corporate Identification Number of our Company is U24233GJ2007PLC049692.

India plays an important role in the global pharmaceuticals and vaccine industry. It is the largest provider of generic medicines globally. The country has a share of 20% in the global supply volume and contributes to around 60% of the global vaccines. India ranks third in the world in terms of volume and is the fourteenth largest in terms of value. Key segments of the Indian pharmaceutical industry are OTC medicines, Generics, APIs, Vaccines, Biosimilars, and Custom Research Manufacturing (CRM). The FMCG sector in India expanded due to consumer-driven growth and higher product prices, especially for essential goods. FMCG sector provides employment to around 3 million people accounting for approximately 5% of the total factory employment in India. FMCG sales in the country was expected to grow 7-9% by revenues in 2022-23. The key growth drivers for the sector include favourable Government initiatives & policies, a growing rural market and youth population, new branded products, and growth of e-commerce platforms. Resilience needs to be the key factor in the manufacturing process, daily operations, retail and logistic channels, consumer insights and communication that will help FMCG companies to withstand the test of time and create more value for consumers in the long run.

We are engaged in the ethical marketing and distribution of pharmaceutical formulation products (Pharma) across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products (FDFP) such as fruits, vegetables, herbs and flowers. We are recognized in the pharmaceutical industry under our own brand name Hamps and in freeze-dried and frozen food segment through our own brand FzyEzy. We sell our products through more than 50 distributor's network as on October 31, 2024 and E-commerce platform, including Amazon.com, Amazon.ca, Amazon.eu, Flipkart, Jio Mart, Etc. We sell our pharma products primarily in 8 States and Union territories and our FDFP products primarily in 6 countries and 22 States and Union territories. As on the date of this Prospectus, we had a range of more than 180 different products sold across both the segments.

Peer Comparison:

  • No Listed Industry Peers

Hamps Bio Limited IPO Key Points

Strengths

  • Expert Leadership and Industry Experience driving Strategic Business Growth.
  • Distribution Network with Expansive E-Retailing Presence.
  • Wide and diversified range of products.
  • Diversified, global customer base with long standing relationships.
  • Wide Geographical Presence.

Risk

  • The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
  • The company does not have its own manufacturing facility for pharmaceutical products and the company has to relies on third parties for procuring pharmaceutical products sold by the Company.
  • Its existing manufacturing facility for freeze dried and frozen products is concentrated in a single region i.e., Ankelshwar, Gujarat and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.

Strategy

  • Capital Expenditure to meet the growing demand of FDFP products.
  • Increasing our Domestic and Global presence.
  • Enhancing our Branding.
  • Reduction of operational costs and achieving efficiency.
  • Strengthen Marketing Network.
  • Expert Leadership and Industry Experience driving Strategic Business Growth.
  • Distribution Network with Expansive E-Retailing Presence.
  • Wide and diversified range of products.
  • Diversified, global customer base with long standing relationships.
  • Wide Geographical Presence.

How To Apply for Hamps Bio Limited IPO Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

Get your FAQs right

Hamps Bio Limited's IPO offers shares for up to ₹ 0 L It begins on Dec 13, 2024 and ends on Dec 17, 2024.

The price of Hamps Bio Limited IPO ranges between NA to NA per share.

The Hamps Bio Limited IPO opens on Dec 13, 2024 and closes on Dec 17, 2024.

The allotment for the Hamps Bio Limited IPO will be finalised on Dec 18, 2024. The shares will be listed on BSE and NSE on Dec 20, 2024.

The minimum lot size for Hamps Bio Limited IPO is 2000 shares, priced between NA to NA per share.

The GMP (Grey Market Premium) of Hamps Bio Limited IPO fluctuates based on market demand and sentiment.

To check the allotment status of Hamps Bio Limited IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

The Hamps Bio Limited IPO is getting listed on the BSE and NSE. Bidding opens on Dec 13, 2024, and closes on Dec 17, 2024. The allotment is finalised on Dec 18, 2024.

To apply for the Hamps Bio Limited IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.